Sansure Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Sansure Biotech has a total shareholder equity of CN¥7.4B and total debt of CN¥409.8M, which brings its debt-to-equity ratio to 5.6%. Its total assets and total liabilities are CN¥8.6B and CN¥1.2B respectively. Sansure Biotech's EBIT is CN¥41.2M making its interest coverage ratio -0.5. It has cash and short-term investments of CN¥4.6B.
Key information
5.6%
Debt to equity ratio
CN¥409.76m
Debt
| Interest coverage ratio | -0.5x |
| Cash | CN¥4.57b |
| Equity | CN¥7.35b |
| Total liabilities | CN¥1.22b |
| Total assets | CN¥8.57b |
Recent financial health updates
Recent updates
Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit
Nov 03
Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings
Oct 09Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital
Oct 03Is Sansure Biotech (SHSE:688289) A Risky Investment?
Sep 12Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected
Aug 21Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital
Jun 03Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems
May 03Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't
Apr 26Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher
Feb 28Financial Position Analysis
Short Term Liabilities: 688289's short term assets (CN¥5.7B) exceed its short term liabilities (CN¥714.3M).
Long Term Liabilities: 688289's short term assets (CN¥5.7B) exceed its long term liabilities (CN¥503.8M).
Debt to Equity History and Analysis
Debt Level: 688289 has more cash than its total debt.
Reducing Debt: 688289's debt to equity ratio has increased from 0% to 5.6% over the past 5 years.
Debt Coverage: 688289's debt is well covered by operating cash flow (49.6%).
Interest Coverage: 688289 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 07:46 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sansure Biotech Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaoling Wang | Chasing Securities |
| Shiyu Chen | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |